{"title":"Importance of genetic testing in childhood cancer survivors for hereditary cancer predisposition syndromes.","authors":"Anja Urbas, Polona Ušaj, Boštjan Šeruga, Mateja Krajc, Simona Hotujec, Vida Stegel, Lorna Zadravec Zaletel","doi":"10.1186/s13053-026-00341-2","DOIUrl":null,"url":null,"abstract":"<p><p>BACKGROUND: Around 10% of children with cancer carry a germline pathogenic or likely pathogenic variant (P/LPV) in one of the cancer predisposition genes. The objective of this study was to evaluate the frequency of genetic testing for hereditary cancer predisposition syndromes (HCPSs) among adults treated for childhood cancer in Slovenia and to characterize the P/LPVs identified in those who opted for genetic testing. We also aimed to analyse how a positive genetic test influences cascade testing in blood relatives. METHODS: We included patients born between 1970 and 2000 who were diagnosed and treated for cancer between ages 0 − 18 into this retrospective, descriptive, cross-sectional study. Data were collected from the Cancer Registry of the Republic of Slovenia, Long-term Follow-Up Clinic (LTFUC) and the Department of Clinical Cancer Genetics (DCCG) databases. The proportion of tested individuals was calculated with a 95% confidence interval (CI) using the Wald’s method. RESULTS: Of 1,475patients diagnosed and treated for cancer in childhood, 59 (4.0%; 95% CI: 3.0–5.0%) underwent genetic testing, with 35.6% (21/59) testing positive. The P/LPV were most frequently found in RB1, NF1, RET and BRCA2 genes. In 61.9% (13/21) of positive cases, an identified cancer predisposition syndrome was linked to the childhood cancer; in 95.2% (20/21) it conferred an increased adult cancer risk. Among six patients with P/LPV and second primary cancer (SPC), two had SPC with possible association with the HCPS. Cascade genetic testing was performed in 38.1% (8/21) of positive families and was documented for 35 relatives of 8 carriers of P/LPV. Overall, 60% (21/35) of relatives were positive at genetic testing and 47.6% (10/21) of developed cancer. In 90% (9/10) of relatives the cancer could be linked to the HCPS. CONCLUSIONS: Only 4% of childhood cancer survivors underwent genetic testing for HCPS. Since hereditary cancer predisposition identified in childhood may also increase cancer risk in adulthood, universal cancer genetic counselling and testing should be considered in childhood to timely enable preventive options for early cancer detection and risk reduction procedures in carriers of P/LPV. In parallel, cascade genetic testing among blood relatives may also offer preventive opportunities to those at risk. </p>","PeriodicalId":55058,"journal":{"name":"Hereditary Cancer in Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13202886/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hereditary Cancer in Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13053-026-00341-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
BACKGROUND: Around 10% of children with cancer carry a germline pathogenic or likely pathogenic variant (P/LPV) in one of the cancer predisposition genes. The objective of this study was to evaluate the frequency of genetic testing for hereditary cancer predisposition syndromes (HCPSs) among adults treated for childhood cancer in Slovenia and to characterize the P/LPVs identified in those who opted for genetic testing. We also aimed to analyse how a positive genetic test influences cascade testing in blood relatives. METHODS: We included patients born between 1970 and 2000 who were diagnosed and treated for cancer between ages 0 − 18 into this retrospective, descriptive, cross-sectional study. Data were collected from the Cancer Registry of the Republic of Slovenia, Long-term Follow-Up Clinic (LTFUC) and the Department of Clinical Cancer Genetics (DCCG) databases. The proportion of tested individuals was calculated with a 95% confidence interval (CI) using the Wald’s method. RESULTS: Of 1,475patients diagnosed and treated for cancer in childhood, 59 (4.0%; 95% CI: 3.0–5.0%) underwent genetic testing, with 35.6% (21/59) testing positive. The P/LPV were most frequently found in RB1, NF1, RET and BRCA2 genes. In 61.9% (13/21) of positive cases, an identified cancer predisposition syndrome was linked to the childhood cancer; in 95.2% (20/21) it conferred an increased adult cancer risk. Among six patients with P/LPV and second primary cancer (SPC), two had SPC with possible association with the HCPS. Cascade genetic testing was performed in 38.1% (8/21) of positive families and was documented for 35 relatives of 8 carriers of P/LPV. Overall, 60% (21/35) of relatives were positive at genetic testing and 47.6% (10/21) of developed cancer. In 90% (9/10) of relatives the cancer could be linked to the HCPS. CONCLUSIONS: Only 4% of childhood cancer survivors underwent genetic testing for HCPS. Since hereditary cancer predisposition identified in childhood may also increase cancer risk in adulthood, universal cancer genetic counselling and testing should be considered in childhood to timely enable preventive options for early cancer detection and risk reduction procedures in carriers of P/LPV. In parallel, cascade genetic testing among blood relatives may also offer preventive opportunities to those at risk.
期刊介绍:
Hereditary Cancer in Clinical Practice is an open access journal that publishes articles of interest for the cancer genetics community and serves as a discussion forum for the development appropriate healthcare strategies.
Cancer genetics encompasses a wide variety of disciplines and knowledge in the field is rapidly growing, especially as the amount of information linking genetic differences to inherited cancer predispositions continues expanding. With the increased knowledge of genetic variability and how this relates to cancer risk there is a growing demand not only to disseminate this information into clinical practice but also to enable competent debate concerning how such information is managed and what it implies for patient care.
Topics covered by the journal include but are not limited to:
Original research articles on any aspect of inherited predispositions to cancer.
Reviews of inherited cancer predispositions.
Application of molecular and cytogenetic analysis to clinical decision making.
Clinical aspects of the management of hereditary cancers.
Genetic counselling issues associated with cancer genetics.
The role of registries in improving health care of patients with an inherited predisposition to cancer.